HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G To Disclose Fragrance Ingredients Portfolio-Wide By 2020

This article was originally published in The Rose Sheet

Executive Summary

NGOs are trumpeting P&G's fragrance disclosure announcement as a major victory for public health and a turning point for the entire consumer products industry. The initiative, which follows a similar move from Unilever in February, will provide visibility into fragrance formulae across more than 2,000 P&G products.

You may also be interested in...



FDA Ban On Flavoring Ingredients Should Prompt Removal From Fragrances – WVE

The battle between hazard and risk ideologies goes on as NGO Women’s Voices for the Earth calls for the removal of five fragrance ingredients from personal-care products that FDA recently – if reluctantly – struck from its list of approved food additives. The agency maintains the substances pose no risk to public health.

Johnson’s Leads J&J On Road To Fragrance Transparency

Beginning with its newly relaunched washes, lotions and hair products, Johnson’s is providing product-specific detail on fragrance components in a transparency move that other J&J skin-care brands will be following, according to a company rep.

J&J Relaunches Johnson’s Baby Care As Greener, Gentler, With Fewer Ingredients

The overhaul in line with “modern parents’ preferences” could be what’s needed to rouse the sleepy brand and spur Consumer business growth.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel